---
title: Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve
nct_id: NCT03427749
overall_status: COMPLETED
sponsor: Ottawa Heart Institute Research Corporation
study_type: OBSERVATIONAL
primary_condition: Coronary Artery Disease
countries: Belgium, Canada, Germany, Italy, Japan, Singapore
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03427749.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03427749"
ct_last_update_post_date: 2025-04-10
last_seen_at: "2026-05-12T07:30:47.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve

**NCT ID:** [NCT03427749](https://clinicaltrials.gov/study/NCT03427749)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 35
- **Lead Sponsor:** Ottawa Heart Institute Research Corporation
- **Collaborators:** GE Healthcare
- **Conditions:** Coronary Artery Disease
- **Start Date:** 2018-10-12
- **Completion Date:** 2022-10-01
- **CT.gov Last Update:** 2025-04-10

## Brief Summary

Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI) ,who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%) and are clinically indicated to have an MBF study.

## Detailed Description

Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI), who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%) and are clinically indicated to have an MBF study. Research imaging will consist of a SPECT acquisition at the time of rest and stress radiotracer injection in addition to the standard (delayed) clinical stress/rest SPECT scan with 99mTc-tetrofosmin. This is an observational study; patients will be managed according to the standard clinical care of the local site. Where available, a CT scan will also be acquired for attenuation and/or scatter correction. Studies may be one day (rest/stress or stress/rest) or two day (rest and stress on separate days) All studies will be analyzed locally but the raw data will also be anonymized and forwarded to the core facility for reprocessing. Central processing will allow comparison between sites and the repeat processing will provide an estimate of inter-operator variability in the measurements. The core lab will also compare the relative perfusion from immediate and delayed imaging for image quality and diagnostic accuracy (visual and quantitative).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18 years old
* BMI ≤ 40 kg/m2
* Able and willing to comply with the study procedures
* Written informed consent
* Intermediate to high probability of CAD
* Suspected or known CAD on a stable medication regime

Exclusion Criteria:

* History or risk of severe bradycardia (heart rate \< 50 beats per minute) not related to chronotropic drugs
* Known second- or third-degree AV block without pacemaker
* Dyspnea (NYHA III/IV), wheezing asthma or COPD
* Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or within 45 days after consent (early revascularization)
* Percutaneous coronary intervention (PCI) within 30 days prior to screening or within 45 days following consent (early revascularization)
* Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
* Known hypersensitivity to dipyridamole or adenosine
* Breastfeeding or pregnancy
* Claustrophobia or inability to lie still in a supine position
* Unwillingness or inability to provide informed consent
```

## Arms

- **SPECT Imaging with 99mTc-Tetrofosmin** — Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI) and who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%). Research imaging will consist of a SPECT acquisition at the time of rest and stress radiotracer injection in addition to the standard (delayed) clinical stress/rest SPECT scan with 99mTc-tetrofosmin

## Interventions

- **SPECT Imaging with 99mTc-Tetrofosmin Research Imaging** (DIAGNOSTIC_TEST) — This is an observational study; patients will be managed according to the standard clinical care of the local site. Study end will be defined as completion of all SPECT imaging at rest and stress. Studies will be acquired at 6 initial sites with mixed prior experience at MBF imaging, to demonstrate feasibility of use in a clinical setting.

## Primary Outcomes

- **Correlation in MBF Between Core Laboratory and Local Site** _(time frame: The average total amount of time that the patient was assessed for the MBF protocol varied between 71 and 122 minutes.)_ — MBF was measured locally and at a core laboratory using commercially available software. The acquisition protocol was standardized between the local site and core laboratory. a one-day rest-stress protocol was used. Relative perfusion images were obtained after tracer injection. All raw study data were transferred to the core laboratory where processing was independently repeated by one reader to evaluate inter site processing consistency. Perfusion scores were compared with the measured MBF.

## Secondary Outcomes

- **Impact on Throughput** _(time frame: The average total time the patient was in the camera room during the study protocol was 72.28 minutes.)_

## Locations (7)

- Universitaire ziekenhuizen Leuven, Leuven, Belgium
- London Health Sciences Centre, London, Ontario, Canada
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Medizinische Hochschule Hannover, Hanover, Germany
- Nuclear Medicine, Università & Spedali Civili, Brescia, Italy, Brescia, Italy
- Ehime University Hospital, Tōon, Japan
- National Heart Center Singapore, Singapore, Singapore

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.universitaire ziekenhuizen leuven|leuven||belgium` — added _(2026-05-12)_
- `locations.london health sciences centre|london|ontario|canada` — added _(2026-05-12)_
- `locations.university of ottawa heart institute|ottawa|ontario|canada` — added _(2026-05-12)_
- `locations.medizinische hochschule hannover|hanover||germany` — added _(2026-05-12)_
- `locations.nuclear medicine, università & spedali civili, brescia, italy|brescia||italy` — added _(2026-05-12)_
- `locations.ehime university hospital|tōon||japan` — added _(2026-05-12)_
- `locations.national heart center singapore|singapore||singapore` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03427749.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03427749*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*